Abstracts

799 – Antiretroviral Treatment Continuity Among Pregnant Women With HIV in Côte d’Ivoire

Background While significant progress has been made in prevention of vertical transmission (VT) of HIV, globally, an estimated 120,000 children acquired HIV in 2024. Sustained antiretroviral treatment (ART) for pregnant and breastfeeding women (PBFW) is critical for HIV viral suppression and reduced risk of VT; however, continuity of ART engagement among PBFW is not widely understood.…

546 – CD4 and CD4/CD8 as Determinants of Long-Term Risk of Clinical Events After ART Initiation in START

Background START trial randomized ART-naïve individuals with CD4>500 cells/μL to immediate or deferred ART until CD4 declined to 350cells/μL or AIDS developed. From 2015, all participants were recommended to initiate ART, followed through 2021. We examined the predictive value of updated immunological biomarkers on long-term clinical outcomes after ART initiation. Methods Cox models assessed risk…

561 – Rising Dolutegravir Resistance in Tanzania: A Concern for the ART Programme

Background In 2020, Tanzania conducted a facility-based national surveillance of HIV drug resistance among people living with HIV (PLHIV). It was observed that 5.8% of PLHIV experiencing high viremia had integrase strand transfer inhibitors (INSTI) drug resistance mutations (DRMs). Therefore, five years later, we aimed to determine the trends and patterns of acquired drug resistance mutations…

1026 – Exploring 7 vs 21 Days of Doxycycline for Chlamydia trachomatis Lymphogranuloma Venereum Strains

Background According to clinical guidelines, Chlamydia trachomatis lymphogranuloma venereum (LGV), unlike non-LGV cases, should be treated with 21-day doxycycline 100 mg twice daily. However, LGV typing is rarely performed in routine care, due to limited availability and turnaround time, so most cases are empirically managed as non-LGV. The aim of the study was to estimate…

292 – HIV-CORE 007 Phase I Trial: Safety and Immunogenicity of T-Cell Vaccines in People With HIV-1

Background The persistence of the HIV-1 reservoir requires lifelong combination antiretroviral therapy (cART). A therapeutic vaccine able to control the virus could limit disease progression and transmission. The HIV-CORE 007 trial evaluated the safety, immunogenicity, and, for the first time, post-treatment virological control of ChAdOx1- and MVA-vectored vaccines expressing conserved HIV-1 mosaic regions (HIVconsvX) in…

314 – Geographic Analysis of Cellular Immunity to Human Cytomegalovirus in Clinical Trial Volunteers

Background Human cytomegalovirus (HCMV) has emerged as a promising vaccine vector given its ability to elicit robust, sustained immune responses and persistent antigen expression. Pre-existing HCMV cellular immunity, which may impact the immunogenicity of CMV-vectored vaccines, is not well characterized across demographic populations.  Methods We conducted an ancillary analysis using data from eligible phase I/II…

907 – Time to First Hospitalization by CD4 Count Among People With HIV in a Large Southeastern Cohort

Background Despite advances in HIV treatment, people with HIV (PWH) remain at elevated risk of hospitalization. While CD4 cell count is a known predictor of HIV-related outcomes, its time-varying relationship with hospitalization risk, especially in recent years, remains poorly understood. We evaluated how risk of first hospitalization following HIV care initiation varies by time-varying CD4…

909 – Factors Associated With the Loss of Elite HIV Control After More Than 20 Years From Diagnosis

Background Persistent exceptional elite controllers (P-EEC) show undetectable HIV-1-RNA levels in plasma by commercially available techniques in the absence of antiretroviral treatment (ART) for more than 20 years and no clinical progression. However, sporadic cases of loss of virological control are being reported in these individuals. At a population level, the incidence of loss of…

928 – Hospital Readmissions Among Adults Aged 50 and Older by HIV Status in Mexico City

Background With the success of antiretroviral therapy, people living with HIV (PLWH) are reaching older ages and increasingly develop multimorbidity, geriatric syndromes as well as higher healthcare use. While hospital-related outcomes in aging PLWH have been described in high-income settings, data from Latin America remain scarce. We aimed to describe hospital readmissions and demographic characteristics…